Min Zheng, Shaoxing Li, Jie Deng, Chaolin Huang, Hua Zhang
{"title":"Identification and Clinical Validation of High HSP60 Expression Predicts Poor Prognosis in Patients with Ovarian Cancer.","authors":"Min Zheng, Shaoxing Li, Jie Deng, Chaolin Huang, Hua Zhang","doi":"10.2147/IJGM.S499524","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the clinical significance of heat shock protein 60 (HSP60) expression in ovarian cancer and evaluate its correlation with patient survival outcomes.</p><p><strong>Methods: </strong>A total of 260 ovarian cancer patients diagnosed between 2017 and 2019 were enrolled. Immunohistochemistry was performed to assess HSP60 expression in tumor tissues. Patients were categorized into high- or low-HSP60 expression groups based on immunohistochemical staining intensity. The correlation between HSP60 expression status and the clinicopathological features of ovarian cancer patients was analyzed. Kaplan-Meier survival curves and Cox regression models were utilized to evaluate overall survival and disease-free survival.</p><p><strong>Results: </strong>HSP60 expression was significantly higher in ovarian cancer tissues compared to normal ovarian tissues. High HSP60 expression was associated with larger tumor size, advanced FIGO stage, and increased lymph node metastasis. Patients with high HSP60 expression exhibited significantly shorter overall survival and disease-free survival than those with low expression. Multivariate Cox analysis identified HSP60 as an independent prognostic factor for both overall survival and disease-free survival.</p><p><strong>Conclusion: </strong>High HSP60 expression is associated with poor prognosis and aggressive tumor characteristics in ovarian cancer. HSP60 may serve as a valuable biomarker for prognosis and a potential therapeutic target. Further randomized clinical trials are warranted to explore its role in ovarian cancer progression and treatment strategies.</p>","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"103-111"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725283/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S499524","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to investigate the clinical significance of heat shock protein 60 (HSP60) expression in ovarian cancer and evaluate its correlation with patient survival outcomes.
Methods: A total of 260 ovarian cancer patients diagnosed between 2017 and 2019 were enrolled. Immunohistochemistry was performed to assess HSP60 expression in tumor tissues. Patients were categorized into high- or low-HSP60 expression groups based on immunohistochemical staining intensity. The correlation between HSP60 expression status and the clinicopathological features of ovarian cancer patients was analyzed. Kaplan-Meier survival curves and Cox regression models were utilized to evaluate overall survival and disease-free survival.
Results: HSP60 expression was significantly higher in ovarian cancer tissues compared to normal ovarian tissues. High HSP60 expression was associated with larger tumor size, advanced FIGO stage, and increased lymph node metastasis. Patients with high HSP60 expression exhibited significantly shorter overall survival and disease-free survival than those with low expression. Multivariate Cox analysis identified HSP60 as an independent prognostic factor for both overall survival and disease-free survival.
Conclusion: High HSP60 expression is associated with poor prognosis and aggressive tumor characteristics in ovarian cancer. HSP60 may serve as a valuable biomarker for prognosis and a potential therapeutic target. Further randomized clinical trials are warranted to explore its role in ovarian cancer progression and treatment strategies.
期刊介绍：
The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas.
A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal.
As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
